Salubris(SZ:002294) Ge Long Hui·2026-01-21 12:06Core Viewpoint - The company, Xinlitai (002294.SZ), announced a change in the use of raised funds for its clinical research projects, reallocating part of the funds to a new hypertension drug project while continuing the original project [1] Group 1: Fund Allocation Changes - The company plans to change the use of part of the raised funds from the "S086 Sacubitril/Valsartan Calcium China II/III Phase Clinical Research and Market Registration Project" to a new project for "Phase II/III Clinical Research and Market Registration of Innovative Hypertension Drugs" [1] - The total investment for the new project is set at 525.71 million yuan, with 301 million yuan coming from the raised funds, accounting for 15.58% of the total raised funds [1] - The company will use its own funds to cover any shortfall in the new project [1] Group 2: Project Timeline Adjustments - Despite the changes in fund allocation, the S086 project will continue to be implemented, with the company also planning to adjust the expected completion date of the S086 project to March 2028 [1]